Document is current
Any future updates will be listed below
-
Authors
Rohm, Theresa
Bochennek, Konrad
Taeuber, Isabel
Klusmann, Jan-Henning
Barnbrock, Anke
Lehrnbecher, Thomas https://orcid.org/0000-0002-6022-3439
- License Information
-
More Information
Article History
Received: 8 November 2025
Revised: 9 December 2025
Accepted: 27 January 2026
First Online: 4 February 2026
Competing interests
: KB served at the speaker´s bureau of Merck/MSD and as consultant to Recordati Pharma. J-HK has advisory roles for Boehringer, Roche and Jazz Pharmaceuticals. AB served at the speaker´s bureau of Merck/MSD. TL has received a grant from Gilead Sciences, has served as consultant to Gilead Sciences, Merck/MSD, Pharming, Mundipharma, Pfizer, Recordati Pharma and Roche, and served at the speaker´s bureau of Gilead Sciences, Merck/MSD, AstraZeneca, Pfizer, Sanofi Pasteur, Recordati Pharma, and Mundipharma. None of the other authors has to declare a conflict of interest regarding this work.
: Written informed consent for data collection and analysis was obtained within the consent procedure for cancer treatment and medical care approved by the local institutional review board (e.g., A105/18, 349/17, 16/0040). All methods were performed in accordance with the relevant guidelines and regulations.
